Medical News

RSS

VAL-083 drug compound shows promise against non-small cell lung cancer

DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.

9 Oct 2014

Allscripts FollowMyHealth Achieve now available for patient engagement innovation

Allscripts has announced the market launch and general availability of Allscripts FollowMyHealth Achieve, a consumer-friendly, patient engagement innovation intended to mobilize and empower patients as active partners in the management of their care.

9 Oct 2014

Astute Medical to get $30 million from CRG to support commercialization of NephroCheck Test System

Astute Medical, Inc. and CRG today announced that Astute recently achieved a milestone under the terms of its existing term loan agreement with CRG. Under the term loan agreement, CRG will provide up to $30 million to support the commercialization of the NephroCheck Test System.

9 Oct 2014

International Biophysics files patent protection for revolutionary AffloVest

International Biophysics Corporation of Austin, Texas announces its filing of U.S. patent protection for its revolutionary AffloVest. The company has also recently confirmed exclusive ownership rights concerning the manufacture, sale and distribution of the AffloVest in its markets.

9 Oct 2014

HemoShear completes first-phase development of novel cancer drug discovery platform

HemoShear today announced that it has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations.

9 Oct 2014

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

9 Oct 2014

Neovasc gets conditional IDE approval from FDA to initiate trial for Tiara mitral valve system

Neovasc Inc. today announced that it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's Tiara™ transcatheter mitral valve.

9 Oct 2014

RPS Diagnostics receives CE mark for FebriDx test

RPS Diagnostics, Inc. today announced CE mark of its FebriDx test, clearing the way for sales in the European Union and all countries recognizing the CE mark.

9 Oct 2014

NanoBio to highlight prophylactic NE HSV-2 vaccine candidate at The Keystone Symposia Conference

NanoBio Corporation today announced that the company will present data at The Keystone Symposia Conference, The Modes of Action of Vaccine Adjuvants, in Seattle on October 12, 2014.

9 Oct 2014

HerStory app helps women with breast cancer to share their voices with other patients

As physicians spend less time with their patients, often as little as 10-15 minutes per appointment, they grow increasingly wary of the limited emotional support they can provide within that time frame.

9 Oct 2014

Exposure to workplace violence can lead to serious consequences for health sector employees

Exposure to violence in the workplace can lead to serious consequences for health sector employees say Stéphane Guay and Nathalie Lanctôt of the Institut universitaire de santé mentale and the University of Montreal, who studied this issue in a systematic review of the literature.

9 Oct 2014

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.

9 Oct 2014

Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Endo International plc and Auxilium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction.

9 Oct 2014

KNCV becomes prime partner for USAID's flagship tuberculosis program

KNCV Tuberculosis Foundation, the Dutch NGO specialized in the fight against tuberculosis, will be the prime partner for the United States Agency for International Development in their new five year flagship program 'Challenge TB'.

9 Oct 2014

Impax executes definitive agreement to acquire Tower Holdings, Lineage Therapeutics

Impax Laboratories, Inc. today announced the execution of a definitive agreement under which Impax will acquire Tower Holdings, Inc., including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC, and Lineage Therapeutics Inc. (together, the "Companies") for $700 million in cash, subject to certain customary purchase price adjustments.

9 Oct 2014

Power grid failure inside injured cardiac cells triggers post-heart attack arrhythmias

Heart attack survivors often experience dangerous heart rhythm disturbances during treatment designed to restore blood flow to the injured heart muscle, a common and confounding complication of an otherwise lifesaving intervention.

9 Oct 2014

Study finds that skin exposure may trigger early peanut allergy in children

Many children may become allergic to peanuts before they first eat them, and skin exposure may be contribute to early sensitization, according to a study in mice led by Mount Sinai researchers and published today in the Journal of Clinical Investigation.

9 Oct 2014

Porvair Sciences appoints SPEware Corporation as its exclusive partner

Porvair Sciences, a world leader in applications optimised microplates and microplate equipment has appointed SPEware Corporation (Baldwin Park, CA) as its exclusive partner for supporting and servicing its UltraVap, MiniVap and UltraVap Mistral microplate sample concentration systems.

From Chromatrap® - Porvair Sciences Ltd 9 Oct 2014

Scientists say fundamental theory about how thymus educates immune police appears to be wrong

A fundamental theory about how our thymus educates our immune police appears to be wrong, scientists say.

9 Oct 2014

Conventional laparoscopy less complicated than robot-assisted surgery for benign gynecologic conditions

For benign gynecologic conditions, robot-assisted surgery involves more complications during surgery and may be significantly more expensive than conventional laparoscopic surgery, according to a study by researchers at Columbia University Medical Center.

9 Oct 2014

Medical News

VAL-083 drug compound shows promise against non-small cell lung cancer

Allscripts FollowMyHealth Achieve now available for patient engagement innovation

Astute Medical to get $30 million from CRG to support commercialization of NephroCheck Test System

International Biophysics files patent protection for revolutionary AffloVest

HemoShear completes first-phase development of novel cancer drug discovery platform

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Neovasc gets conditional IDE approval from FDA to initiate trial for Tiara mitral valve system

RPS Diagnostics receives CE mark for FebriDx test

NanoBio to highlight prophylactic NE HSV-2 vaccine candidate at The Keystone Symposia Conference

HerStory app helps women with breast cancer to share their voices with other patients

Exposure to workplace violence can lead to serious consequences for health sector employees

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

KNCV becomes prime partner for USAID's flagship tuberculosis program

Impax executes definitive agreement to acquire Tower Holdings, Lineage Therapeutics

Power grid failure inside injured cardiac cells triggers post-heart attack arrhythmias

Study finds that skin exposure may trigger early peanut allergy in children

Porvair Sciences appoints SPEware Corporation as its exclusive partner

Scientists say fundamental theory about how thymus educates immune police appears to be wrong

Conventional laparoscopy less complicated than robot-assisted surgery for benign gynecologic conditions

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Membrane proteins in focus: Turning high-risk targets into routine workflows

Latest News